经导管与外科肺动脉瓣置换的系统综述与荟萃分析
该系统综述与荟萃分析比较了经导管肺动脉瓣置换(TPVR)与外科肺动脉瓣置换(SPVR)的临床结局。共纳入比较两种技术的文献,主要终点为术后早期死亡率。结果显示两组围术期死亡率无差异,TPVR 减少手术相关并发症和住院时间,但中期感染性心内膜炎风险显著增高。
要点
- TPVR 与 SPVR 围术期死亡率无显著差异(0.2% vs 1.2%,P=.27)。
- TPVR 显著减少手术相关并发症并缩短住院时间。
- TPVR 组中期感染性心内膜炎发生率显著高于 SPVR 组(5.8% vs 2.7%,P<.001)。
核心结论
- 在选定患者中 TPVR 是 SPVR 的安全替代方案,住院时间更短且手术相关并发症更少。
- 中期随访时 TPVR 与 SPVR 在死亡率和再干预需求方面相当,但 TPVR 的感染性心内膜炎风险增加。
研究设计与样本
- 系统综述与荟萃分析,检索 Medline 和 Cochrane 数据库自建库至 2019 年 1 月及相关参考文献。
- 纳入比较 TPVR 与 SPVR 并报告研究终点比较数据的研究。
主要发现
- 围术期死亡率两组无差异(0.2% vs 1.2%;合并 OR 0.56;95%CI 0.19-1.59;P=.27;I2=0%)。
- TPVR 组手术相关并发症和住院时间显著减少。
- 中期死亡率和再干预需求两种技术相似。
- 合并感染性心内膜炎在 TPVR 组显著更常见(5.8% vs 2.7%;合并 OR 3.09;95%CI 1.89-5.06;P<.001;I2=0%)。
- TPVR 与随访期更少的显著肺动脉反流相关,并呈现跨肺动脉收缩期压差更低的趋势。
临床怎么用
- 对于选定的肺动脉瓣功能障碍患者,TPVR 可作为外科手术的替代选择,但需权衡感染性心内膜炎风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcatheter pulmonary valve replacement (TPVR) has emerged as an alternative to surgery in patients with pulmonary valve dysfunction. METHODS: We searched the Medline and Cochrane databases since their inception to January 2019 as well as references from article, for all publications comparing TPVR with surgical PVR (SPVR). Studies were considered for inclusion if they reported comparative data regarding any of the study endpoints. The primary endpoint was early mortality after PVR. Secondary endpoints included procedure-related complications, length of hospital stay, mortality during follow-up, infective endocarditis, need for reintervention, post-PVR transpulmonary peak systolic gradient, and significant pulmonary regurgitation. RESULTS: There were no differences in perioperative mortality between groups (0.2% vs 1.2%; pooled odds ratio, 0.56; 95% confidence interval, 0.19-1.59; P = .27, I2 = 0%). However TPVR conferred a significant reduction in procedure-related complications and length of hospital stay compared with SPVR. Midterm mortality and the need for repeat intervention were similar with both techniques, but pooled infective endocarditis was significantly more frequent in the TPVR group (5.8 vs 2.7%; pooled odds ratio, 3.09; 95% confidence interval, 1.89-5.06; P < .001, I2 = 0%). TPVR was associated with less significant PR and a trend towards a lower transpulmonary systolic gradient during follow-up. CONCLUSIONS: TPVR is a safe alternative to SPVR in selected patients and is associated with a shorter length of hospital stay and fewer procedure-related complications. At midterm follow-up TPVR was comparable with SPVR in terms of mortality and repeat intervention but was associated with an increased risk of infective endocarditis.
引用
- Ribeiro JM, Teixeira R, Lopes J, et al. Transcatheter Versus Surgical Pulmonary Valve Replacement: A Systemic Review and Meta-Analysis. Ann Thorac Surg. 2020. PMID: 32268142. doi:10.1016/j.athoracsur.2020.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。